# First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI

Source: https://onco.cc/trials/nct05920135/  
OnCo record `nct05920135` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of BBT-207 in non-small-cell lung cancer, run by Bridge Biotherapeutics, Inc., active and no longer recruiting.

## Summary

First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI is a phase 1/2 interventional study registered as NCT05920135 by Bridge Biotherapeutics, Inc., with 24 participants enrolled, started 2023-09-11 and due to reach its primary completion in 2026-08-01. Interventions recorded: BBT-207.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05920135
- Phase: 1/2
- Setting: First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI
- Sponsor: Bridge Biotherapeutics, Inc.
- Enrolled: 24

## Sources

- ClinicalTrials.gov NCT05920135: https://clinicaltrials.gov/study/NCT05920135

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)

---
JSON: https://onco.cc/api/v1/entities/nct05920135.json